Elevated serum IL-34 is correlated with disease severity in patients with biliary atresia following Kasai portoenterostomy

医学 胆道闭锁 胃肠病学 内科学 病态的 瞬态弹性成像 胆红素 肝移植 肝活检 活检 移植
作者
Sittisak Honsawek,Nichaphat Bovornsethanant,Thamonwan Woraruthai,Paisarn Vejchapipat,Wanvisa Udomsinprasert,Yong Poovorawan
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:127: 111356-111356
标识
DOI:10.1016/j.intimp.2023.111356
摘要

Biliary atresia (BA) is a severe congenital disorder with progressive obstructive cholangiopathy in young children. The inflammatory process has been recognized as one of the pathological mechanisms driving bile duct injury. Since interleukin-34 (IL-34) has been reportedly linked to several pathological liver disorders, including inflammation, the current study aimed to analyze circulating IL-34 and the association of circulating IL-34 with hepatic deterioration and clinical outcomes in post-Kasai BA children.Circulating IL-34 levels were analyzed in 89 post-Kasai BA subjects and 45 healthy individuals using an ELISA. Liver stiffness (hardness) was measured by ultrasound elastography.Circulating IL-34 was substantially higher in BA children than in control individuals, particularly those with unfavorable outcomes including hepatic dysfunction, jaundice, and portal hypertension. In BA group, circulating IL-34 was positively correlated with liver stiffness (r = 0.515, p < 0.001), AST (r = 0.403, p < 0.001), ALT (r = 0.279, p = 0.008), total bilirubin (r = 0.224, p = 0.03), ALP (r = 0.255, p = 0.016), and serum IL-6 (r = 0.590, p < 0.001) but inversely correlated with albumin (r = -0.417, p < 0.001). Kaplan-Meier survival analysis showed that higher circulating IL-34 levels were significantly associated with reduced survival rates in BA subjects (p = 0.002).Higher circulating IL-34 values were directly associated with hepatic impairment and the BA severity, implicating thatserum IL-34 could be applied as a noninvasive marker for the monitoring of the severity in BA subjects following Kasai portoenterostomy and therapeutic efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
庞伟泽完成签到,获得积分10
1秒前
英姑应助机灵似狮采纳,获得10
1秒前
dcc发布了新的文献求助10
1秒前
秀兰完成签到,获得积分10
2秒前
畅快的胡萝卜完成签到,获得积分10
2秒前
韩小小完成签到 ,获得积分10
3秒前
TiAmo发布了新的文献求助10
3秒前
大明完成签到,获得积分10
3秒前
杨辉发布了新的文献求助10
3秒前
3秒前
fddd发布了新的文献求助10
3秒前
wenchong完成签到,获得积分20
3秒前
4秒前
4秒前
wjw完成签到,获得积分10
4秒前
jt完成签到,获得积分10
4秒前
xiangxl完成签到,获得积分10
4秒前
doclarrin完成签到 ,获得积分10
4秒前
菜鸡L完成签到,获得积分10
5秒前
搜集达人应助dll采纳,获得10
6秒前
忽忽完成签到,获得积分10
6秒前
1313131完成签到,获得积分10
6秒前
小二郎应助MHY采纳,获得10
7秒前
John_sdu完成签到,获得积分10
7秒前
邢晓彤完成签到 ,获得积分10
8秒前
所所应助君君君采纳,获得10
8秒前
顺心醉蝶完成签到 ,获得积分10
8秒前
zhouzhou完成签到,获得积分10
9秒前
9秒前
小蘑菇应助缥缈的绿兰采纳,获得10
9秒前
快乐友易发布了新的文献求助10
9秒前
Kuta完成签到,获得积分10
11秒前
折光发布了新的文献求助10
12秒前
嘻嘻嘻完成签到,获得积分10
12秒前
13秒前
Hayat应助平淡天曼采纳,获得30
13秒前
13秒前
团子团子猪完成签到,获得积分10
14秒前
zyb发布了新的文献求助10
14秒前
wssamuel完成签到,获得积分10
15秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
TOWARD A HISTORY OF THE PALEOZOIC ASTEROIDEA (ECHINODERMATA) 1000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
The Social Work Ethics Casebook(2nd,Frederic G. R) 600
Handbook of Social and Emotional Learning 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5118837
求助须知:如何正确求助?哪些是违规求助? 4324693
关于积分的说明 13473527
捐赠科研通 4157793
什么是DOI,文献DOI怎么找? 2278607
邀请新用户注册赠送积分活动 1280375
关于科研通互助平台的介绍 1219167